Facts & figures
As of: January, 2019
1) primarily from public funds (EU, Federal Government, State Government); according to Campus Buch: total funding since 1992, incl. BIMSB
2) primarily from own ressources, since 2001
3) primarily from own ressources
4) since 2009
5) since 2006
6) since 2002
| Research Institutions of Campus Berlin-Buch Employees (total) |
2,151 |
|
| of these: | ||
| Max Delbrück Center for Molecular Medicine (MDC): | 1,646 | |
| Leibniz Institute of Molecular Pharmacology (FMP): | 303 | |
| Klinische Forschung Charité Campus Buch: | 202 | |
| Budget and third-party grants (total)1 | EUR 192 million | |
| Max Delbrück Center for Molecular Medicine (MDC): | EUR 147 million | |
| Leibniz Institute of Molecular Pharmacology (FMP): | EUR 29 million | |
| Klinische Forschung Charité Campus Buch: | EUR 16 million | |
| BiotechPark Berlin-Buch | ||
| Number of companies: | 62 | |
| Employees: | 800 | |
| Annual revenue: Percentage of third-party grants: 3,1% |
EUR 220 million |
|
| Hospitals & Patient-Care Institutions | ||
| Employees (total): of these: |
3,564 | |
| HELIOS Klinikum Berlin-Buch: | 2,700 | |
| Evangelische Lungenklinik: | 325 | |
| Immanuel Krankenhaus Berlin, Standort Buch (Rheumaklinik): | 89 |
|
| Patient-care institutions: | 450 | |
| Number of patient beds: | 1,267 | |
| Patients per year (inpatient and outpatient): | 220,519 | |
| Total investment volume of these: |
EUR 1.451 billion | |
| Infrastructure Campus Berlin-Buch1 | EUR 624 million | |
| HELIOS Klinikum Berlin-Buch² | EUR 336 million | |
| Evangelische Lungenklinik3 | EUR 49 million | |
| Immanuel Krankenhaus Berlin, Standort Buch (Rheumaklinik)1 | EUR 39 million |
|
| LudwigPark 3 | EUR 45 million | |
| Allées des Châteaux 3 | EUR 23 million | |
| Widerker Vermögensverwaltung (Schlosspark-Passage) 3 | EUR 29 million |
|
| Ludwig Hoffmann Quartier | EUR 152 million |
|
| Housing construction associations (HOWOGE 3,4, EWG 3,5, WBG 3,6 Hau+S 3,5 ) | EUR 154 million |
News Buch Berlin
A fresh take on proteomics
Start-up company Absea Biotechnology GmbH is developing new proteomics technologies. An interview with Dr. Philip Lössl, Senior VP Science and Business Development
more ...A double-pronged attack on malignant B cells
Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In “Molecular Therapy,” a team led by Armin Rehm presents an improved immunotherapy that ...
more ...A new opportunity for Berlin
The Einstein Center for Early Disease Interception has been funded with six million euros. In an interview, Nikolaus Rajewsky and Leif Erik Sander, both spokespeople of the center, explain why new tec...
more ...Events Buch Berlin
26.01.2026, 16:00
Einfach Wissen: Desinformation als Strategie? Neue Spielarten politischen Handelns im digitalen Raum
Im Auftakt der neuen Reihe "Einfach Wissen" von rbb24 und der Technologiestiftung Berlin zeigt Prof. Dr. Jeanette Hofmann, welche Rolle Falschinformationen bei denjenigen spielen, die sich von der Dem...
more ...28.01.2026, 16:00
Labor trifft Lehrer*in: Wie Hirnorganoide helfen, Therapien für Neuroentwicklungs- krankheiten zu entwickeln
Vortrag von Jakob Metzger, Max Delbrück Center: Seltene genetische Veränderungen können die Entwicklung des menschlichen Gehirns tiefgreifend beeinflussen und neurologische Erkrankungen verursachen – ...
more ...28.01.2026, 17:00
"Musik trifft Wissenschaft" Bucher Campus-Klassikkonzert
mit den Pianisten Tabea und Daniel Streicher, die Werke von Ravel, Bartok, Bach u.a. spielen
more ...
